At the 58th American Society of Hematology (ASH) Annual Meeting & Exposition, John Gribben, MD, DSc, and Stephan Stilgenbauer, MD,…
Browsing: Acute Lymphoblastic Leukemia
At the 58th American Society of Hematology (ASH) Annual Meeting & Exposition, John Gribben, MD, DSc, and Stephan Stilgenbauer, MD,…
At the 58th American Society of Hematology (ASH) Annual Meeting & Exposition, John Gribben, MD, DSc, and Stephan Stilgenbauer, MD,…
At the 58th American Society of Hematology (ASH) Annual Meeting & Exposition, John Gribben, MD, DSc, and Stephan Stilgenbauer, MD,…
Simon Rule, MD from Derriford Hospital, Plymouth, UK provides an overview of the side-effects of ibrutinib, based on data presented…
Simon Rule, MD from Derriford Hospital, Plymouth, UK provides an overview of the RAY (MCL3001) study of ibrutinib vs temsirolimus…
Simon Rule, MD from Derriford Hospital, Plymouth, UK provides an overview of Bruton’s tyrosine kinase inhibitors (BTK) in chronic lymphocytic…
There is an increasing spectrum of available therapies for patients with cancer, which has improved the outcomes of varied cancer…
Mohamad Mohty, MD, PhD, from Saint-Antoine Hospital, Paris, France, summarises data on the management of patients with multiple myeloma that…
At the 58th American Society of Hematology (ASH) Annual Meeting & Exposition, Robin Foà , MD, from Sapienza University, Rome, Italy,…
Paul Richardson, MD from the Dana-Farber Cancer Institute Medical Oncology, Boston, MA provides an overview of the Tourmaline-MM1 study of…
Jean-Jacques Kiladjian, MD, PhD from the Saint-Louis Hospital & Paris Diderot University, Paris, France provides an overview of the COMFORT-II…
Paul Richardson, MD from the Dana-Farber Cancer Institute Medical Oncology, Boston, MA talks about the use of elotuzumab for the…
Andrew Zelenetz, MD, PhD from the Memorial Sloan-Kettering Cancer Center, New York, NY discusses common side-effects observed in the Phase…
Paul Richardson, MD from the Dana-Farber Cancer Institute Medical Oncology, Boston, MA provides an overview of the 3-year update presented…
At the 58th American Society of Hematology (ASH) Annual Meeting & Exposition, Roy Denis-Claude, MD, from Maisonneuve-Rosemont Hospital and Montreal…
At the 58th American Society of Hematology (ASH) Annual Meeting & Exposition, Keith Stewart, MB, ChB, from Mayo Clinic, Scottsdale,…
At the 58th American Society of Hematology (ASH) Annual Meeting & Exposition, Keith Stewart, MB, ChB, from Mayo Clinic, Scottsdale,…
At the 58th American Society of Hematology (ASH) Annual Meeting & Exposition, Keith Stewart, MB, ChB, from Mayo Clinic, Scottsdale,…
Rafael Fonseca, MD from the Mayo Clinic, Scottsdale, AZ talks about the new therapies in multiple myeloma, such as ixazomib,…
Rafael Fonseca, MD from the Mayo Clinic, Scottsdale, AZ discusses the new methods used to measure treatment response in multiple…
Rafael Fonseca, MD from the Mayo Clinic, Scottsdale, AZ provides an overview of a clinical trial (IFM 2013-04) of bortezomib…
Andrew Zelenetz, MD, PhD from the Memorial Sloan-Kettering Cancer Center, New York, NY provides an overview of a clinicogenetic risk…
Andrew Zelenetz, MD, PhD from the Memorial Sloan-Kettering Cancer Center, New York, NY provides an overview of a Phase III…
At the 58th American Society of Hematology (ASH) Annual Meeting & Exposition, Catherine Bollard, MBChB, MD, FRACP, FRCPA, from Children’s…
At the 58th American Society of Hematology (ASH) Annual Meeting & Exposition, Catherine Bollard, MBChB, MD, FRACP, FRCPA, from Children’s…
Andrew Zelenetz, MD, PhD from the Memorial Sloan-Kettering Cancer Center, New York, NY provides an overview of a few new…
Patient Power founder Andrew Schorr visits with Dr. Michael Keating of MD Anderson Cancer Center to ask audience questions about…
Multiple myeloma expert Dr. Robert Orlowski responds to a question from a Patient Power community member related to access to…
Can we interrupt the fibrotic process? MPN expert Dr. Srdan Verstovsek of MD Anderson Cancer Center explains PRM-151, and how…
Which CLL patients benefit most from chemotherapy? CLL expert Dr. Nicole Lamanna explains the various therapeutic agents currently in use,…
Francesco Annibale d’Amore, MD, PhD from Aarhus University, Aarhus, Denmark talks about the Nordic Lymphoma Group (NLG) study on the…
At the 58th American Society of Hematology (ASH) Annual Meeting & Exposition Sagar Lonial, MD, from Emory University Winship Cancer…
At the 58th American Society of Hematology (ASH) Annual Meeting & Exposition, Sagar Lonial, MD, from Emory University Winship Cancer…
Sagar Lonial, MD from Emory University Winship Cancer Institute, Atlanta, GA gives an overview of the ELOQUENT-2 clinical trial of…
A biosimilar can be defined as a biological product that demonstrates no clinically meaningful differences to an approved biological product.…
Claire Harrison of the Guy’s and St. Thomas Hospital in London, UK, talks about how in the UK, clinicians have…
Claire Harrison, MD of the Guy’s and St. Thomas Hospital in London, UK, talks about the molecular architecture of myeloproliferative…
Claire Harrison, MD of the Guy’s and St. Thomas Hospital in London, UK, talks about panobinostat (LBH589), commonly used for…
Claire Harrison, MD of the Guy’s and St. Thomas Hospital in London, UK, gives an overview of the latest results…
At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December…
Since the approval of the first antibody-drug conjugate or ADC, now more than 15 years ago, scientists and researchers have…
Gareth Morgan, MD, FRCP, FRCPath, PhD from the University of Arkansas for Medical Sciences, Arkansas, AR discusses the current treatment…
Joseph R Mikhael, MD from the Mayo Clinic, Scottsdale, AZ talks about new drugs being used for the treatment of…
Joseph R Mikhael, MD from the Mayo Clinic, Scottsdale, AZ provides an overview of a Phase II clinical trial of…
Gareth Morgan, MD, FRCP, FRCPath, PhD from the University of Arkansas for Medical Sciences, Arkansas, AR provides an overview of…
Jeremy Abramson, MD, from the Massachusetts General Hospital, Massachusetts, MA discusses the highlights of the American Society of Hematology (ASH)…
Starting in February 2016, ADC Review / Journal of Antibody-drug Conjugates will offer select (video) interviews with KOLs (Key Opinion…
Fresh from the 2015 American Society of Hematology (ASH) conference, Dr. Michael Mauro of Memorial Sloan Kettering Cancer Center delves…
Where do we stand with CAR-T therapy? Could checkpoint inhibitors apply in CLL? CLL expert Dr. William Wierda, from the…